Vybion - Protein Innovations

News

Press Release, For Immediate Release

May 14, 2008

Vybion, Inc., an Ithaca-based biotechnology company, today announced that it has executed a letter of intent to sell its recombinant protein business to Meridian Bioscience, Inc. (NASDAQ: VIVO). The planned transaction, which both Vybion and Meridian expect will be completed within the next 60 days, calls for Vybion to receive both cash and future royalties based on sales of the applicable products, the amounts of which were not disclosed. Completion of the transaction is subject to execution of a definitive purchase agreement, satisfactory due diligence, and other customary conditions.

Dr. Lee Henderson, founder and CEO of Vybion, explained "This is an excellent opportunity for both companies. For Vybion it means that we can focus and internally fund proprietary activities, namely moving CoMab, our monoclonal antibody preclinical drug for Cocaine abuse, forward and commercialize our ProCode Platform technology.

For further information, contact Lee Henderson (607-266-0860).

Vybion Awarded Monoclonal Antibody Development Contract.

April 11, 2007

Ithaca, NY: Vybion, Inc. was awarded a contract by P2D in Cincinnati as part of collaboration on an SBIR Phase II grant. Vybion is developing a humanized version of the monoclonal antibody genes, developing the expression lines and the process for manufacturing the product. The antibody, specific for cocaine, binds cocaine in the blood stream, causing cocaine in brain tissues to cross the blood brain barrier back into the blood where it remains bound to the antibody prior to detoxification in liver. More (4KB)

Vybion Licenses ProCode™ Platform

January 22, 2007

Ithaca, NY: Vybion has exclusively licensed a drug development platform from Cornell University. The Platform, called ProCode, can be configured for monoclonal antibody selection, affinity maturation and library generation, for improving solubility and bioactivity of biopharmaceuticals, as well as identification and characterization of protein-protein interactions and discovery of protein drugs. ProCode offers several important advantages that strongly differentiate it from other technologies including dramatic reductions in drug development time, cost, and ease of use. More (5KB)

Vybion Presents at PepTalk Conference

January 8, 2007

Vybion CEO, Lee Henderson, Ph.D., made a poster presentation at the annual PepTalk Conference in San Diego on the ProCode Technology with work done by Matthew DeLisa, Ph.D. and his group in the Department of Chemical and Molecular Engineering at Cornell University. The poster centered on the applications of the ProCode twin arginine transport system for affinity improvement of monoclonal antibodies and solubility improvement of a variety of biologics. Several examples of the technology were presented. ProCode is a Platform technology for drug development that saves time, cost and is easy to use as well.

Herpes Virus Sublicense

November 16, 2006

Vybion has expanded its license from Novartis (formerly Chiron) on Herpes Virus recombinant proteins. Vybion now can not only manufacture these proteins, but it can also develop, manufacture and sell diagnostic kits with rights to sublicense these activities. The Company intends to aggressively pursue market expansion and sublicensing opportunities worldwide.